GeneDx and Prognos Health Partner to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options

Rare Daily Staff

GeneDx and Prognos Health entered a strategic partnership to shorten the treatment odyssey for rare disease patients via real world data.

“Patients with rare diseases oftentimes have to endure a diagnostic odyssey of approximately eight years, meaning that not months, but years are wasted without an accurate diagnosis and without knowledge of or access to an FDA-approved therapy,” said Kareem Saad, chief transformation officer of GeneDx. “This partnership gives us the opportunity to go a step further to connect clinicians and their patients with rare diseases to appropriate treatment options and ultimately improve health and health economic outcomes.”

GeneDx has a genetic database enriched for rare diseases with samples from more than 1.3 million patients, including more than 450,000 exomes and genomes. Prognos’ Marketplace includes lab and health records on more than 325 million de-identified patients, as well as claims data, pharmacy prescription data, among other data types.

The partnership offers life science companies a comprehensive de-identified dataset specific to rare diseases to accelerate access to life saving therapies. Prognos Marketplace will integrate GeneDx’s de-identified rare disease data, including regularly updated data as GeneDx continues to add new genomic and health information retrieved through its whole genome and whole exome sequencing tests. Biopharma companies who work with Prognos will then be automatically alerted about clinicians who have newly diagnosed patients and may benefit from therapies that have been approved by the U.S. Food and Drug Administration.

“Prognos Health’s mission has always been to unlock the power of data to improve health, and this partnership further enables us to provide actionable insights in rare disease that can help clinicians make more informed decisions and ensure patients receive the right treatment at the right time,” said Sundeep Bhan, CEO of Prognos Health. “With the rare disease genomics data and expertise available to us through partners like GeneDx, our life science clients can leverage the Prognos Marketplace to bring about a paradigm shift in the treatment of rare diseases.”

Photo: Sundeep Bhan, CEO of Prognos Health